# Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase

> **NCT07555678** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 241 (estimated)

## Conditions studied

- Anal Squamous Cell Cancer

## Interventions

- **DRUG:** PD-1 Inhibitor + Chemotherapy

## Key facts

- **NCT ID:** NCT07555678
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 241 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07555678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07555678, "Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07555678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*